Skip to content

Psychiatric and Cognitive Manifestations of Parkinson's Disease

Psychiatric and Cognitive Manifestations of Parkinson's Disease: A Prospective Cohort Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00360633
Enrollment
36
Registered
2006-08-04
Start date
2006-06-30
Completion date
2019-03-28
Last updated
2019-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Keywords

Parkinson's Disease, Impulse control disorder, Dopamine agonist withdrawal syndrome, Anxiety, Depression, Healthcare Utilization, Disability, Quality of life, Cognitive function, Psychosis, Apathy, Dyskinesias, Wearing off

Brief summary

Parkinson's Disease (PD) is often thought of as affecting movement only. In fact, most patients also experience psychiatric and cognitive symptoms, sometimes from the disease itself, and sometimes as a side-effect of PD medications. The goals of this study are to evaluate the causes, effects, and clinical correlates of psychiatric and cognitive symptoms in PD.

Detailed description

Parkinson's Disease (PD) is defined by the presence of motor symptoms, but in recent years there has been increasing recognition of non-motor manifestations, including anxiety, depression, and cognitive symptoms. In addition, PD medications have been shown to cause impulse control disorders, cognitive changes, and non-motor withdrawal symptoms (dopamine agonist withdrawal syndrome) when they are discontinued. The goals of this study are to test the hypothesis that the presence of psychiatric and cognitive symptoms are associated with greater self-perceived disability (out of proportion to objective deficits), increased utilization of healthcare resources, and decreased quality of life. In addition, we will examine the clinical correlates of these psychiatric symptoms. To test these hypotheses, we will screen PD patients for anxiety, depression, impulse control disorders, and dopamine agonist withdrawal syndrome, and compare cases and controls with regard to demographic characteristics, motor features of PD, disability, healthcare utilization, and quality of life.

Interventions

None listed

Sponsors

NYU Langone Health
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Diagnosis of idiopathic Parkinson's Disease (or healthy control subject) * Age \>=21 and \<=99 * Capacity to provide informed consent * Ability to complete the questionnaires

Exclusion criteria

* Clinical diagnosis of dementia * Terminal illness (life expectancy \< 12 months) * Presence of a neurodegenerative disorder other than Parkinson's Disease

Design outcomes

Primary

MeasureTime frame
Non-motor symptom progressionChronic

Secondary

MeasureTime frame
Motor symptom progressionChronic

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026